Thymic carcinoma

Related records

Broader conditions (21)

• Cancer
• Cancer or benign tumor
• Carcinoma
• Disease
• Disease by body system or component
• Disease by etiologic mechanism
• Endocrine gland neoplasm
• Endocrine system disorder
• Epithelial neoplasm
• Hematologic disorder
• Hematopoietic and lymphoid system neoplasm
• Human disease
• Immune system cancer
• Immune system disorder
• Malignant endocrine neoplasm
• Neoplasm
• Neoplastic disease or syndrome
• Thymic epithelial neoplasm
• Thymus cancer
• Thymus gland disorder

Narrower conditions (18)

• Invasive malignant thymoma
• Lymphoepithelioma-like thymic carcinoma
• Malignant type AB thymoma
• Moderately-differentiated thymic neuroendocrine carcinoma
• Papillary thymic adenocarcinoma
• Poorly differentiated thymic neuroendocrine carcinoma
• Thymic adenosquamous carcinoma
• Thymic basaloid carcinoma
• Thymic large cell neuroendocrine carcinoma
• Thymic mucoepidermoid carcinoma
• Thymic neuroendocrine carcinoma
• Thymic sarcomatoid carcinoma
• Thymic undifferentiated carcinoma
• Thymus clear cell carcinoma
• Thymus gland adenocarcinoma
• Thymus small cell carcinoma
• Thymus squamous cell carcinoma
• Well-differentiated thymic neuroendocrine carcinoma

Trials (47)

• A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies
• A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies
• A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors
• A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy
• A Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors
• A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
• A Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma
• A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
• A Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma
• Artificial Intelligence Prediction Tool in Thymic Epithelial Tumors
• Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced Stage
• Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma
• CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors
• Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma
• Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
• Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
• Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy
• Electrocautery Resection Combined With HITHOC for Thymic Epithelial Tumors With Pleural Metastasis
• Genomic Profiling of Nodular Thyroid Disease and Thyroid Cancer
• Hypofractionated Adjuvant Radiotherapy for Thymic Epithelial Tumors

Drugs in development (56)

• Amrubicin Phase 2
• Amrubicin hydrochloride Phase 2
• Antilymphocyte immunoglobulin (horse) Phase 2
• Atezolizumab Phase 2
• Avelumab Phase 2
• Belinostat Phase 2
• Bevacizumab Phase 2
• Bintrafusp alfa Phase 2
• Busulfan Phase 2
• Capecitabine Phase 1
• Carboplatin Phase 2
• Catequentinib Phase 2
• Celecoxib Phase 1
• Cetuximab Phase 2
• Cisplatin Phase 2
• Cixutumumab Phase 2
• Cyclophosphamide Phase 2
• Docetaxel Phase 2
• Domvanalimab Phase 2
• Doxorubicin Phase 1